<DOC>
	<DOC>NCT01868802</DOC>
	<brief_summary>A randomized multicentric parallel arms study involving the use of ketamine for treatment-resistant depression will be held at three national health provider clinics in the Mexican population. The purpose of this study is to determine whether clinical response seen in previous studies is replicable in this population.</brief_summary>
	<brief_title>Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Age: 1865 years old Mayor Depressive Disorder Diagnosis based on DSMIV TR. Classification of MDD as treatmentresistant. No brain structural abnormalities as evidenced by an MRI scan. Signed acceptance of Informed Consent. Other psychiatric diagnosis apart from MDD. Substance abuse or dependence (prior or during study). Pregnancy. Congestive heart disease. Personal history of psychosis. Firstdegree relative with history of psychosis. Glaucoma. Present neurological disease. High blood or pulmonary artery pressure. Declining the signing of the informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Ketamine</keyword>
	<keyword>Depression</keyword>
	<keyword>Depressive Disorder</keyword>
</DOC>